Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07801300 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)

Name: A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein) — clinical trial record (NCT07801300)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorEli Lilly and Company

Started2026-09

View on ClinicalTrials.gov ↗

The main purpose of this study is to evaluate the safety and tolerability of LY5625575 in healthy participants (including Japanese and Chinese) and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also measure how much LY5625575 gets into the bloodstream and how long it takes the body to get rid of it. The study will last seven to nine weeks.

Trial Details

NCT Number	NCT07801300
Lead Sponsor	Eli Lilly and Company
Conditions	Healthy Volunteers, C-Reactive Protein
Enrollment	204 participants
Start Date	2026-09
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-09-03